The final data from a trial in Guinea, published in The Lancet, showed zero cases of Ebola among the 5,837 people vaccinated immediately after contact with an infected person. Among those who received the vaccine three weeks later, 23 cases developed. The ring vaccination strategy, which targeted the contacts of infected individuals, turned the tide. The vaccine, developed by the Public Health Agency of Canada and licensed to Merck, used a vesicular stomatitis virus engineered to carry an Ebola virus protein. It was not a theoretical breakthrough but a field-tested tool.
Its importance was immediate and practical. The trial began in 2015 during the catastrophic West African outbreak that killed over 11,000 people. Previous interventions relied on isolation and containment, methods strained by the scale of the epidemic. The vaccine provided a proactive weapon. The 70-100% efficacy range reflected real-world conditions where precise exposure timing was unknown, not uncertainty about the vaccine's potency.
A common misunderstanding is that the vaccine was invented in 2016. Its development began years earlier, but the 2014-2016 crisis created the tragic urgency and ethical imperative for rapid clinical testing. The breakthrough was not the science alone, but the proof gathered under extreme duress.
The lasting impact is a reconfiguration of epidemic response. VSV-EBOV, now called Ervebo, gained WHO prequalification in 2019, enabling its use in subsequent outbreaks in the Democratic Republic of the Congo. It established a model for outbreak vaccine development and deployment, shifting the paradigm from purely defensive containment to targeted immunological offense.